WaveMan
WaveMan · Company
FOCL · Edap Tms Sa
> Search tickers & screens ⌘K
LIVE
← All companies

FOCL Edap TMS (FOCL) Insider Trading, Ownership & Congress Trades

Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001041934
Quote by TradingView
Cluster · 4 insidersC-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
15
13F, latest reported quarter

What the filings say about FOCL

Insiders, 180 days
+$408.5K net bought
4 buyers

Edap TMS insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, EDAP TMS SA insiders bought a net $408.5K of stock across 4 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
WILLSEY LANCE
Director
BUY
2026-08-17 SECtraded 2026-08-14
50,000
$237.5K
-0.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 3.9% of the 1,291,780 shares held after it.
  • 3 other insiders bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WILLSEY LANCE bought about $237.5K of FOCL on Aug 14, 2026, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.
Rhodes Ryan
Chief Executive Officer
BUY
2026-08-17 SECtraded 2026-08-14
21,000
$99.8K
-0.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 3.4% of the 626,649 shares held after it.
  • 3 other insiders bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Rhodes Ryan bought about $99.8K of FOCL on Aug 14, 2026, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.
Shah Sanket
General Counsel & Corp Sec
BUY
2026-08-17 SECtraded 2026-08-14
5,000
$23.8K
-0.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 6.9% of the 72,500 shares held after it.
  • 3 other insiders bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel & Corp Sec Shah Sanket bought about $23.8K of FOCL on Aug 14, 2026, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.
Schulz Fran
Director
BUY
2026-08-17 SECtraded 2026-08-14
10,000
$47.5K
-0.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 66.2% of the 15,100 shares held after it.
  • 3 other insiders bought within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schulz Fran bought about $47.5K of FOCL on Aug 14, 2026, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.
4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$408.5K over 180 days
+$408.5K over 90 days
more than 85% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
15 funds bought in last quarter
below 76% of Medical Devices
Revenue
+1.6% year over year
below 73% of Medical Devices
Margin
-41.5% net margin
below 65% of Medical Devices
Buybacks
no share repurchases reported
Short interest
0.8% of the float short (float per yahoo 2026-10-26) · 2.9 days to cover · settled 2026-09-30
below 76% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch FOCL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+76.2%12M
-25%+38%+101%+164%2025-102025-122026-022026-042026-062026-082026-10 2026-08-14 · WILLSEY LANCE bought $237.5K2026-08-14 · Rhodes Ryan bought $99.8K2026-08-14 · Schulz Fran bought $47.5K2026-08-14 · Shah Sanket bought $23.8K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns FOCL: institutional holders (13F)

13F holdings, latest reported quarter
Soleus Capital Management, L.P.
7,309,254 sh
$37.9M
MORGAN STANLEY
3,336,872 sh
$17.3M
Rock Springs Capital Management LP
1,386,000 sh
$7.2M
FLAX POND CAPITAL, LLC
1,525,676 sh
$6.8M
Bruce & Co., Inc.
438,652 sh
$2.3M

Congress trades in FOCL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

FOCL planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

FOCL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
1290 Essex Small Cap Growth Fund
$764.8K position · as of 2026-07-31
0.7%
BRUCE FUND
$2.1M position · as of 2026-06-30
0.6%
Fidelity Nasdaq Composite Index Fund
$98.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.7M
$2.7M
$860.5K
-38%
n/a
2024
$1.3M
$768.6K
$738.1K
-58%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $408.5K bought by insiders over 180 days, 15 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

FOCL financials

Revenue growth
+1.6%
XBRL, annual
Net margin
-41.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$175.2M
market value at close 2026-10-26 on 2026-08-14 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$70.5M$69.4M$60.4M$55.1M
Gross profit$30.0M$28.7M$24.4M$24.2M
Operating income-$24.7M-$22.2M-$19.8M-$4.3M
Net income-$29.2M-$20.6M-$21.2M-$2.9M
EPS (diluted)-0.78-0.55-0.57-0.09
Operating cash flow-$16.4M-$14.7M-$14.7M-$3.0M
Cash$20.5M$31.0M$43.5M$63.1M
Long-term debt$15.9M$2.2M$2.0M$3.6M
SEC XBRL, fiscal years, as known on 2026-10-28

FOCL Stock Sonar score 4/7 axes

Find similar shapesCompare

FOCL ranks highest on risk and compliance (90th percentile) and insider conviction (88th), and lowest on institutional and government (24th), among Medical Devices peers.

Growth
27
Inputs
  • Revenue growth, YoY+1.6% · 27 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
88
Inputs
  • Net Form 4 buying (codes P and S), 180d$408K · 85 pct, sector of 140
  • Insider buyers, 180d4 · 91 pct, sector of 142
Institutional and government
24
Inputs
  • Funds adding, latest quarter15 · 24 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
90
Inputs
  • Short interest, % of float+0.8% · 80 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Financial health, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; needs four quarters of operating cash flow
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

FOCL filings, in plain words

Are Edap TMS insiders buying or selling FOCL?

In the 180 days to 2026-10-28, Edap TMS insiders were net buyers, a net $408.5K across purchases and sales reported on Form 4, by 4 buyers.

Read the full summary

In the 180 days to 2026-10-28, Edap TMS insiders were net buyers of FOCL, a net $408.5K across purchases and sales reported on Form 4 by 4 buyers. 4 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies